Executive Remuneration Framework Outlook As outlined in letters from the Chair and CEO earlier in this report, a number of strategic initiatives are being undertaken in FY26 to improve clinical and commercial execution and to help reduce cost and complexity. One of the key strategic initiatives is to progress toward the demerger of CSL Seqirus, our vaccines business. Should the demerger proceed, a review of the remuneration frameworks for each business will be required. The Board will provide updates on the progress of this initiative and the impact on both CSL’s and Seqirus’s remuneration frameworks. Your Board will continue to review CSL’s remuneration framework to ensure it can compete in a global market and can attract and retain the highest quality talent to help deliver enduring patient impact in areas of high unmet medical need. This includes benchmarking against our global pharmaceutical and biotechnology peers. We will continue to talk to and seek feedback from our stakeholders over the coming months to make sure their views are considered. Thank you to my fellow Human Resources and Remuneration Committee members and thank you for supporting CSL and the patients we serve around the world. Dr Megan Clark AC Chair Human Resources and Remuneration Committee 2025 Financial Highlights NPATA US$3,219M 14% on prior year at constant currency Sustainability 4 of 5 priorities achieved at or above target NPAT US$3,002M 17% on prior year at constant currency ROIC 11.5% up from 10.5% in prior year CFO US$3,561M 29% on prior year EPS US$6.20 13% 63 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3